Phase II study of weekly topotecan with bevacizumab in platinum resistant recurrent ovarian, fallopian tube and primary peritoneal cancers
Phase of Trial: Phase II
Latest Information Update: 22 May 2015
At a glance
- Drugs Bevacizumab (Primary) ; Topotecan (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 25 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Oct 2006 New trial record.